Breast cancer
Conditions
Interventions
experimental group:NEPA+Acupoint application therapy
Control group1:NEPA+ DEX + Acupoint application therapy(placebo)
Control group2:NEPA+ Acupoint application therapy(placebo)
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Patients are informed agree and sign the written Informed Consent voluntarily participate; 2) Patients aged 20 to 65 yearsgender is not limited 3) patients with malignant solid tumors by clinically diagnosed ; 4) patients who received a chemotherapy regimen based on anthracycline drugs including but not limited to anthracycline combined with cyclophosphamide as well as any previously administered highly emetic chemotherapy for other malignant tumors; 5) Patients with ECOG score is 0 or 1 and the expected survival time is = 3 months; 6) Patients who plan to undergo the first cycle of chemotherapy based on anthracycline drugs including but not limited to anthracycline combined with cyclophosphamide and/or co use with other low emetic or low potential drugs (including but not limited to 5-fluorouracil methotrexate etc.); 7) Liver and kidney functions were in the normal range(serum transaminase not higher than 2 times the upper limit of normal value and serum creatinine level is not higher than 1.5 times the upper limit of normal value); 8) patients has the ability and willingness to complete diaries and research questionnaires.
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications to chemotherapy; 2) Patients with severe liver and kidney dysfunction; 3) DEX absolute contraindications; 4) NEPA allergy sufferers; 5) Patients with major organ failure such as decompensated heart and lung failure; 6) Patients with other serious illnesses or infections that may be life-threatening during the treatment period; 7) Patients with skin allergies; 8) Pregnant women lactating women or women who may become pregnant; 9) Patients with mental disorders and epilepsy patients; 10) Patients who have participated in any clinical trials within the past 3 months prior to being selected; 11) Other researchers believe that it is not suitable to be included in this trial; 12) There are other health issues that may interfere with CINV symptoms such as gastrointestinal diseases migraines and tinnitus; 13) Symptomatic brain metastasis; 14) Gastrointestinal obstruction or active peptic ulcer; 15) Long term use of systemic corticosteroids (excluding local and inhaled corticosteroids) or any other medication with antiemetic potential;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate and complete control rate of delayed nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anticipated nausea and vomiting;Complete remission rate and complete control rate of acute nausea and vomiting;Appetite and quality of life; | — |
Countries
China
Contacts
Public ContactYu Fei
Shengjing Hospital of China Medical University
Outcome results
None listed